Relieves osteoarthritis and rheumatoid arthritis. ANDA 90445, held by Annora Pharma. Nabumetone.
As of Nov 15, 2026, ANDA 90445 (Nabumetone), held by Annora Pharma, was first approved by FDA on Jan 12, 2011, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets USP and other treatment options before deciding to use nabumetone tablets USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets USP are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 12, 2011 | Original application | Approved | None posted |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
| Nov 21, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 12, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters